Healthcare Services

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Developments and Growth Opportunities Across 2026–2030

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Evolve From 2026 To 2030?

The market for chemotherapy-induced nausea and vomiting (cinv) has experienced robust growth over recent years. This market is projected to expand from $3.13 billion in 2025 to $3.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be ascribed to several factors, including the increasing application of highly emetogenic chemotherapy, greater recognition of treatment side effects, the introduction of advanced antiemetic medications, the broadening of oncology treatment initiatives, and enhanced clinical directives for managing cinv.

The market for chemotherapy-induced nausea and vomiting (cinv) is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $4.57 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this anticipated growth include a heightened demand for advanced antiemetics, the increasing embrace of tailored antiemetic treatments, the broadening of outpatient chemotherapy provisions, an intensified focus on complying with treatment guidelines, and developments in formulations designed for sustained release. Key developments expected during this period encompass a greater acceptance of combined antiemetic strategies, increased utilization of prolonged-release cinv medications, an evolving emphasis on care models centered around patients, the proliferation of preventive cinv management strategies, and a stronger focus on improving patients’ quality of life.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

What Major Drivers Are Influencing Demand In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

The expanding incidence of cancer is projected to boost the chemotherapy-induced nausea and vomiting (CINV) market in the coming period. Cancer refers to a condition where certain bodily cells proliferate uncontrollably and metastasize to other areas. With the ongoing rise in cancer diagnoses, there’s a stronger impetus to create more potent and focused anti-emetic therapies to mitigate CINV, a severe consequence of chemotherapy. This sharpened emphasis on managing CINV has resulted in progress in comprehending its fundamental mechanisms and in devising new treatments. For example, in January 2023, the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, reported that in the United States, an estimated 1.9 million new cancer cases (roughly 5,370 cases daily) and 609,820 cancer deaths (around 1,670 deaths daily) are expected in 2023. Consequently, the growing occurrence of cancer will propel the chemotherapy-induced nausea and vomiting (CINV) market.

Which Segment Areas Are Covered In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Analysis?

The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –

1) By Form: Injectables, Oral, Transdermal Patches

2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes

3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

Subsegments:

1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

2) By Oral: Tablets, Capsules, Liquid Formulations

3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

Which Trends Are Influencing The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Leading companies active in the chemotherapy-induced nausea and vomiting (CINV) market are developing innovative products, such as fixed intravenous antiemetics, to achieve a competitive edge. A fixed intravenous antiemetic denotes a specific dose of medicine delivered via an IV to avert or treat nausea and vomiting, frequently utilized during chemotherapy or after surgery. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based producer of pharmaceuticals, generics, and over-the-counter (OTC) items, released AKYNZEO I.V. in India. This was the first fixed intravenous antiemetic combination crafted to prevent chemotherapy-induced nausea and vomiting (CINV). The product merges netupitant and palonosetron, addressing both the immediate and delayed phases of nausea and vomiting. It offers the benefit of single-dose convenience, leads to improved complete response rates, and enhances the quality of life for cancer patients. Clinical investigations demonstrate its notable effectiveness for patients receiving highly emetogenic chemotherapy.

Which Global Companies Are Actively Competing In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

Read the full chemotherapy-induced nausea and vomiting (cinv) market report here:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chemotherapy-Induced Nausea and Vomiting (CINV) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026, By The Business Research Company

Myeloproliferative Disorders Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Chemotherapy Induced Anemia Global Market Report

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Chemotherapy Global Market Report

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795